Angiotensin-converting enzyme (ACE)

Overview

Angiotensin-converting enzyme (ACE) is a key regulatory enzyme of the renin–angiotensin system, as explained in the document. It plays a central role in blood pressure regulation, fluid balance, and cardiovascular homeostasis. ACE is primarily located on the endothelial cells of the lungs, although it is also present in other tissues. Its main physiological function is to convert angiotensin I into angiotensin II, a potent vasoconstrictor that increases blood pressure by narrowing blood vessels.

In addition to this role, Angiotensin-converting enzyme is responsible for the degradation of bradykinin, a natural vasodilator. By reducing bradykinin levels, ACE further promotes vasoconstriction. The document highlights that Angiotensin-converting enzyme activity directly influences salt and water retention, electrolyte balance, sympathetic nervous system activity, and aldosterone secretion. Because of these actions, Angiotensin-converting enzyme is crucial in maintaining cardiovascular and renal stability. Measurement of ACE levels in blood is clinically useful, particularly in the evaluation and monitoring of granulomatous diseases such as sarcoidosis.

Symptoms

Angiotensin-converting enzyme itself does not cause symptoms; instead, symptoms are related to conditions associated with altered ACE levels, especially elevated levels. According to the document, raised Angiotensin-converting enzyme levels are commonly seen in sarcoidosis and other granulomatous disorders, leading to a wide range of systemic symptoms.

Common symptoms associated with raised ACE levels include:

1. Persistent dry cough
2. Shortness of breath or wheezing
3. Chest pain
4. Extreme tiredness or fatigue
5. Fever and night sweats

Additional symptoms may include:

1. Joint pain and stiffness
2. Headache
3. Dry mouth
4. Red, watery eyes or vision problems
5. Unexplained weight loss and loss of appetite
6. Skin changes such as rashes, sores, or hardened patches

The document notes that symptoms vary depending on the organs involved, with lungs, skin, eyes, lymph nodes, liver, and joints being commonly affected.

Causes

According to the document, elevated ACE levels occur due to increased production of the enzyme by activated inflammatory cells, particularly those present at the borders of granulomas. Granulomas are clusters of immune cells formed during chronic inflammation and are characteristic of sarcoidosis and similar disorders.

Conditions associated with increased ACE levels include:

1. Sarcoidosis
2. Granulomatous inflammatory diseases
3. Chronic lung involvement
4. Certain metabolic and systemic disorders

The document also explains that excessive ACE activity leads to increased angiotensin II levels, resulting in sustained vasoconstriction, fluid retention, and increased blood pressure. Conversely, decreased ACE levels may be seen in conditions such as starvation, renal disease, obstructive pulmonary disease, and hypothyroidism. Additionally, ACE inhibitor therapy significantly lowers measured ACE levels by blocking enzyme activity.

Risk Factors

Risk factors for altered ACE levels are closely linked to inflammatory, granulomatous, cardiovascular, and metabolic conditions, as outlined in the document.

Major risk factors include:

1. Clinical or radiological suspicion of sarcoidosis
2. Chronic inflammatory or granulomatous diseases
3. Persistent respiratory symptoms of unknown origin
4. Lymphadenopathy or unexplained organ inflammation

Additional risk factors include:

1. Liver disease
2. Endocrine disorders such as hyperthyroidism or hyperparathyroidism
3. Diabetes mellitus
4. Chronic lung disease
5. Systemic conditions associated with granuloma formation

The document also highlights that the use of ACE inhibitors is a significant factor influencing test results, as these medications markedly reduce serum ACE activity and may interfere with disease assessment.

Prevention

Angiotensin-converting enzyme abnormalities cannot be directly prevented, as they result from underlying disease processes rather than lifestyle factors alone. However, the document outlines preventive strategies focused on early detection, accurate evaluation, and appropriate monitoring.

Preventive and best-practice measures include:

1. Early ACE testing when granulomatous disease is suspected
2. Monitoring ACE levels to assess disease activity and treatment response
3. Correlating ACE results with clinical findings and imaging
4. Avoiding misinterpretation of results in patients receiving ACE inhibitor therapy

For proper testing and result reliability, the document emphasizes:

1. No special preparation is required before testing
2. Collection of 3.0 mL blood in a plain red-capped tube
3. Early separation of serum and prompt laboratory processing
4. Awareness that ACE inhibitor therapy significantly reduces ACE levels

The document stresses that prevention in this context means preventing complications through early diagnosis, accurate interpretation, and careful monitoring, rather than preventing ACE production itself. Correct clinical correlation ensures optimal patient management and avoids diagnostic errors.